Media Centre
© Enthera. All rights reserved
Enthera Srl, Via Visconti di Modrone, 18, 20122 Milan, Italy
T: +39 02 49533580
E: info@entherapharmaceuticals.com
Enthera Srl, Via Visconti di Modrone, 18, 20122 Milan, Italy
T: +39 02 49533580
E: info@entherapharmaceuticals.com
This website uses only technical cookies and does not perform any profiling or collection of personal data through cookies. Simply browsing the website does not require the user’s consent.
Website by Instinctif Partners
Enthera Pharmaceuticals raises €28 million in Series A financing to advance restorative therapy for type 1 diabetes and inflammatory bowel disease
/in Press ReleasesMilan, Italy – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the completion of a €28 million Series A financing round.
Enthera, the first spin-off of BiovelocITA, completed €4 million seed-expansion financing
/in Press ReleasesEnthera, an innovative Italian start-up dedicated to the research and development of innovative therapeutics to treat Type 1 Diabetes and gastrointestinal diseases, received an investment of €4 million led by Sofinnova along with the JDRF T1D Fund (the venture capital fund of the authoritative US JDRF Foundation dedicated to promoting research on Type 1 Diabetes), the accelerator BiovelocITA and its shareholders.
Enthera and Trianni Announce Licensing Agreement
/in Press ReleasesTrianni, Inc. (“TRIANNI”) and Enthera, S.r.L. (“ENTHERA”) jointly announced today that ENTHERA has entered into a license agreement for The Trianni Mouse™, a best-in-class monoclonal antibody discovery platform.